Literature DB >> 20062101

Regression modeling of competing risk using R: an in depth guide for clinicians.

L Scrucca1, A Santucci, F Aversa.   

Abstract

We describe how to conduct a regression analysis for competing risks data. The use of an add-on package for the R statistical software is described, which allows for the estimation of the semiparametric proportional hazards model for the subdistribution of a competing risk analysis as proposed by Fine and Gray. J Am Stat Assoc 1999; 94: 496-509.

Mesh：

Year:  2010        PMID： 20062101     DOI： 10.1038/bmt.2009.359

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


  130 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.

Authors:  Koen van Besien; Wendy Stock; Elizabeth Rich; Olatoyosi Odenike; Lucy A Godley; Peter H O'Donnell; Justin Kline; Vu Nguyen; Paula Del Cerro; Richard A Larson; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2011-11-09       Impact factor: 5.742

3.  Preemptive antiviral therapy for CMV infection in allogeneic stem cell transplant recipients guided by the viral doubling time in the blood.

Authors:  C Solano; E Giménez; J L Piñana; V Vinuesa; S Poujois; S Zaragoza; M Calabuig; D Navarro
Journal:  Bone Marrow Transplant       Date:  2015-12-07       Impact factor: 5.483

4.  Survival analysis in the presence of competing risks.

Authors:  Zhongheng Zhang
Journal:  Ann Transl Med       Date:  2017-02

5.  Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.

Authors:  Muthu Veeraputhiran; Lingyao Yang; Vandana Sundaram; Sally Arai; Robert Lowsky; David Miklos; Everett Meyer; Lori Muffly; Robert Negrin; Andrew Rezvani; Judith Shizuru; Wen Kai Weng; Laura Johnston
Journal:  Biol Blood Marrow Transplant       Date:  2017-06-28       Impact factor: 5.742

6.  Atypical and anaplastic meningioma: outcomes in a population based study.

Authors:  T Garzon-Muvdi; W Yang; M Lim; H Brem; J Huang
Journal:  J Neurooncol       Date:  2017-04-20       Impact factor: 4.130

7.  Implantable Cardioverter-Defibrillators With Versus Without Resynchronization Therapy in Patients With a QRS Duration >180 ms.

Authors:  Varun Sundaram; Jayakumar Sahadevan; Albert L Waldo; George J Stukenborg; Yogesh N V Reddy; Samuel J Asirvatham; Judith A Mackall; Anselma Intini; Brigid Wilson; Daniel I Simon; Kenneth C Bilchick
Journal:  J Am Coll Cardiol       Date:  2017-04-25       Impact factor: 24.094

8.  Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.

Authors:  Sherif S Farag; Mohammad Abu Zaid; Jennifer E Schwartz; Teresa C Thakrar; Ann J Blakley; Rafat Abonour; Michael J Robertson; Hal E Broxmeyer; Shuhong Zhang
Journal:  N Engl J Med       Date:  2021-01-07       Impact factor: 91.245

9.  Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.

Authors:  Michael E Belloy; Valerio Napolioni; Summer S Han; Yann Le Guen; Michael D Greicius
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

10.  Pneumonia in the Noninstitutionalized Older Population.

Authors:  Lutz P Breitling; Kai-Uwe Saum; Ben Schöttker; Bernd Holleczek; Felix J Herth; Hermann Brenner
Journal:  Dtsch Arztebl Int       Date:  2016-09-16       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.